Elexacaftor/tezacaftor/ivacaftor could be produced via generic companies for a fraction of the list price. The current pricing model restricts access to the best available therapy, thereby exacerbating existing inequalities in CF care. Urgent action is needed to increase the availability of triple combination treatment worldwide. One strategy based on previous success is originator-issued voluntary licenses.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2022) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: